Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21571709 | 0.83 | MGLL (0.78) | MGLL | |
| SCHEMBL21571718 | 0.81 | MGLL (1.00) | MGLL | |
| SCHEMBL20136981 | 0.79 | MGLL (1.00) | MGLL | |
| SCHEMBL20136988 | 0.78 | MGLL (1.00) | MGLL | |
| SCHEMBL20137016 | 0.76 | MGLL (0.84) | MGLL | |
| SCHEMBL19992911 | 0.75 | MGLL (0.63) | MGLL | |
| SCHEMBL20137133 | 0.75 | MGLL (1.00) | MGLL | |
| SCHEMBL21571696 | 0.75 | MGLL (0.81) | MGLL | |
| SCHEMBL21571695 | 0.74 | MGLL (1.00) | MGLL | |
| SCHEMBL20136952 | 0.74 | MGLL (1.00) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MGLL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.